{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:18:48Z","timestamp":1762859928164,"version":"build-2065373602"},"reference-count":16,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015550","name":"Ministry of Health","doi-asserted-by":"publisher","award":["HK.03.01\/1\/6211\/2021"],"award-info":[{"award-number":["HK.03.01\/1\/6211\/2021"]}],"id":[{"id":"10.13039\/501100015550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Numerous studies have proved the efficacy of vaccination in reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and the coronavirus disease (COVID-19) burden. However, even though the COVID-19 vaccination coverage is high for primary doses, a booster dose is needed to sustain protection. Continuing our previous research, this study evaluates the immunogenicity and safety of full and half doses of two COVID-19 booster vaccines, ChAdOx1-S (AstraZeneca) and BNT162b2 (Pfizer-BioNTech), in individuals primed with ChAdOx1-S. Methods: This study was an observer-blind randomized controlled trial to evaluate the immunogenicity and safety of half and full doses of two COVID-19 booster vaccine types, BNT162b2 and ChAdOx1-S, among fully vaccinated, ChAdOx1-S-primed individuals in Jakarta, Indonesia. A total of 329 participants were randomized to receive either full or half doses of the booster vaccines, namely the ChAdOx1-S and BNT162b2 COVID-19 vaccines. Immunogenicity was assessed through SARS-CoV-2 antibody titers and neutralizing antibodies (NAbs) at 28 days post-booster, while safety was monitored via adverse event reporting. Results: The results showed that both vaccines demonstrated increased geometric mean titers (GMTs) post-booster. In the ChAdOx1-S booster group, at the baseline visit (day 0) and third visit (day 28), no statistically significant differences in GMT between the half- and full-dose groups were observed (p = 0.970 and 0.539, respectively). In the BNT162b2 group, no statistically significant difference was noted at the baseline visit, while the full dose was higher than the half dose at 28 days (Day 28, p = 0.011). Surrogate virus neutralization tests (sVNTs) and NAbs assays also revealed no significant differences between the half and full dose groups for both the Wuhan strain and the Delta variant. The BNT162b2 group compared to the ChAdOx1-S group revealed a statistically significant increase in IgG levels compared to ChAdOx1-S, with p-values of &lt;0.001 and &lt;0.001 for the half dose and full dose, respectively. This was also reflected in the NAbs test results, where BNT162b2 showed significantly higher levels against both the Wuhan strain and Delta variant. Adverse events were predominantly mild: 79.6% (n = 86\/108) in the ChAdOx1-S full-dose group, 75.4% (n = 43\/57) in the ChAdOx1-S half-dose group, 84.2% (n = 101\/120) in the BNT162b2 full-dose group, and 92.6% (n = 88\/95) in the BNT162b2 half-dose group, with pain at the injection site being the most common local reaction and myalgia and headache the most frequent systemic reactions. One serious adverse event was reported, assessed as unrelated to the vaccine. Conclusions: This study confirms that half doses of ChAdOx1-S and BNT162b2 are as immunogenic and safe as full doses, and a heterologous booster is more immunogenic than a homologous booster.<\/jats:p>","DOI":"10.3390\/vaccines13111149","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:56:27Z","timestamp":1762858587000},"page":"1149","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial"],"prefix":"10.3390","volume":"13","author":[{"given":"Nina Dwi","family":"Putri","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-2359","authenticated-orcid":false,"given":"Aqila Sakina","family":"Zhafira","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratama","family":"Wicaksana","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hindra Irawan","family":"Satari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-1740","authenticated-orcid":false,"given":"Eddy","family":"Fadlyana","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivi","family":"Safitri","sequence":"additional","affiliation":[{"name":"Tambora Primary Health Care Center, Jakarta 11320, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurlailah","family":"Nurlailah","sequence":"additional","affiliation":[{"name":"Tambora Primary Health Care Center, Jakarta 11320, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwinaditya Sekar","family":"Putri","sequence":"additional","affiliation":[{"name":"Senen Primary Health Care Center, Jakarta 10410, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidya","family":"Putri","sequence":"additional","affiliation":[{"name":"Senen Primary Health Care Center, Jakarta 10410, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi Surya","family":"Iriyani","sequence":"additional","affiliation":[{"name":"Pasar Minggu Primary Health Care Center, Jakarta 12510, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunita Sri","family":"Ulina","sequence":"additional","affiliation":[{"name":"Pasar Minggu Primary Health Care Center, Jakarta 12510, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8343-6647","authenticated-orcid":false,"given":"Frizka","family":"Aprilia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evi","family":"Pratama","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indri","family":"Nethalia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Yustisiana","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlin Qur\u2019atul","family":"Aini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7046-2185","authenticated-orcid":false,"given":"Rini","family":"Fajarani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adityo","family":"Susilo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulya Rahma","family":"Karyanti","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-239X","authenticated-orcid":false,"given":"Ari","family":"Prayitno","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadyana","family":"Sukandar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Watts","sequence":"additional","affiliation":[{"name":"New Vaccines Research Group, Murdoch Children\u2019s Research Institute (MCRI), Melbourne 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Mazarakis","sequence":"additional","affiliation":[{"name":"New Vaccines Research Group, Murdoch Children\u2019s Research Institute (MCRI), Melbourne 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pretty","family":"Multihartina","sequence":"additional","affiliation":[{"name":"National Institute of Health Research & Development, Jakarta 10560, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-7909","authenticated-orcid":false,"given":"Vivi","family":"Setiawaty","sequence":"additional","affiliation":[{"name":"National Institute of Health Research & Development, Jakarta 10560, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisna Nur Andriana","family":"Pangesti","sequence":"additional","affiliation":[{"name":"National Institute of Health Research & Development, Jakarta 10560, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-9767","authenticated-orcid":false,"given":"Agnes Rengga","family":"Indrati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julitasari","family":"Sundoro","sequence":"additional","affiliation":[{"name":"The Indonesian Technical Advisory Group on Immunization, Jakarta 10560, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7704","authenticated-orcid":false,"given":"Dwi Oktavia","family":"Handayani","sequence":"additional","affiliation":[{"name":"Jakarta Health Agency, Jakarta 10120, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy B.","family":"Kartasasmita","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Rezeki","family":"Hadinegoro","sequence":"additional","affiliation":[{"name":"The Indonesian Technical Advisory Group on Immunization, Jakarta 10560, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[{"name":"New Vaccines Research Group, Murdoch Children\u2019s Research Institute (MCRI), Melbourne 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2025, October 28). World Health Organization COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/vaccines?n=c."},{"key":"ref_5","unstructured":"(2025, October 28). Vaksin Dashboard. Available online: https:\/\/vaksin.kemkes.go.id\/#\/vaccines."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2091865","DOI":"10.1080\/21645515.2022.2091865","article-title":"Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults","volume":"18","author":"Niyomnaitham","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(22)00800-3","article-title":"Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: A randomised, observer-masked, controlled trial in Indonesia","volume":"23","author":"Fadlyana","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","unstructured":"(2024, November 10). Pedoman Pencegahan Dan Pengendalian Coronavirus Disesase (COVID-19). Available online: https:\/\/infeksiemerging.kemkes.go.id\/document\/pedoman-pencegahan-dan-pengendalian-covid-19\/view."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"English, E., Cook, L.E., Piec, I., Dervisevic, S., Fraser, W.D., and John, W.G. (2021). Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods. J. Clin. Microbiol., 59.","DOI":"10.1128\/JCM.00288-21"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105269","DOI":"10.1016\/j.jcv.2022.105269","article-title":"Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays","volume":"155","author":"Kannenberg","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref_12","unstructured":"(2024, November 10). Reflection Paper on the Regulatory Requirements for Vaccines Intended to Provide Protection Against Variant Strain(s) of SARS-CoV-2. Available online: https:\/\/www.pei.de\/SharedDocs\/Downloads\/EN\/newsroom-en\/hp-news\/ema-paper-variations-covid-19.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s43856-022-00119-2","article-title":"Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients","volume":"2","author":"Wong","year":"2022","journal-title":"Commun. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","article-title":"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: A prospective, longitudinal population-based study","volume":"3","author":"Barin","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/14760584.2024.2315089","article-title":"Comparing reactogenicity of COVID-19 vaccine boosters: A systematic review and meta-analysis","volume":"23","author":"Smith","year":"2024","journal-title":"Expert Rev. Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1149\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:16:12Z","timestamp":1762859772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111149"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111149","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}